SecBot SecBot
8-K ·Filed Nov 9, 2026

RFL

Rafael Holdings, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7d 9h ago SEC0001213900-26-117552
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The FDA's Day 60 filing decision on December 27, 2026 will determine whether the NDA is accepted for review and whether priority review is granted. The mixed Phase 3 results (missed primary endpoint but positive prespecified subgroup) create regulatory uncertainty. Monitor the filing decision and any advisory committee briefing documents for the FDA's view on the efficacy data.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

RFL drug pipeline →

remibetadex

◆ Mixed Named in this 8-K
Impact
Phase
Filed/PDUFA (NDA submitted)
Time to market
If the FDA accepts the NDA for filing, a standard review would take 10 months from filing acceptance, with a potential PDUFA date in late 2027. Priority review (if granted) could shorten this to 6-8 months. The FDA has 60 days from the October 28 submission to decide on filing acceptance.
Next catalyst
None dated

What to watchThe next catalyst is the FDA's filing decision within approximately 60 days (by late December 2026). If the NDA is accepted, a PDUFA target action date will be assigned. If rejected, the stock could face significant downside given the Phase 3 primary endpoint miss. Watch for any financing announcements given the $22.1M cash balance and ongoing burn rate.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.07
T+0 close · Nov 9, 2026 · via day close
Latest settled
+1.87%
T+1 · $1.09 · next T+5 in 5h
Vs SPY
+0.55%
α at T+1
Latest observation
−5.32%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $1.07entry
  2. T+1 · 6d ago +1.87%α +0.55% · $1.09
  3. T+4 · todayOpen
  4. T+5 · in 5h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rafael Holdings filed an 8-K furnishing an investor presentation that reviews Phase 3 topline data for remibetadex in Niemann-Pick disease type C (NPC). The primary endpoint was not statistically significant (p=0.19), but a prespecified analysis in patients on miglustat/leucine showed a 71% relative slowing of disease progression (p=0.046). An NDA was submitted to the FDA in October 2026 with a potential PDUFA target around mid-2027 if priority review is granted.

Key Facts

  • Phase 3 TransportNPC primary endpoint (4DNPCSS change at Week 96) not statistically significant: difference 0.81, p=0.19
  • Prespecified analysis in patients on miglustat/leucine (n=78) showed 71% relative slowing of disease progression, difference 1.11, p=0.046
  • NDA submitted to FDA in October 2026; Day 60 filing decision expected Dec. 27, 2026
  • Potential PDUFA target date ~June 2027 if priority review granted
  • Cash balance of approximately $22.1M as of July 31, 2026
  • Company evaluating financing and strategic options for NDA review and launch
  • Rare Pediatric Disease PRV program extended to September 2029; recent four vouchers sold for average ~$200M
  • Serious TEAEs occurred more frequently with remibetadex (35.9%) vs placebo (16.7%)

Financial Impact

No revenue or earnings reported; $22.1M cash balance; potential commercial opportunity in NPC market expected to exceed $920M by 2033

cashdilution

Risk Factors

  • Phase 3 primary endpoint was not statistically significant, which may complicate FDA review
  • Company has substantial doubt about ability to continue as a going concern and needs additional capital
  • FDA may not accept the NDA for filing, grant priority review, or approve remibetadex
  • Serious adverse events were more frequent in the remibetadex arm (35.9% vs 16.7%)
  • Remibetadex has not received regulatory approval and may never be commercialized

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-117552
Document: ea0311540-8k_rafael.htm0001213900-26-117552
Document: 0001213900-26-117552-index-headers.html0001213900-26-117552
Document: 0001213900-26-117552-index.html0001213900-26-117552
Document: 0001213900-26-117552.txt0001213900-26-117552

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026